首页> 生物试剂> 抗体和免疫分析> ELISA> Palivizumab ELISA Kit,96T,DK421028-96T,Abinscience

Palivizumab ELISA Kit,96T,DK421028-96T,Abinscience

销售价: ¥ 6756.00 / 件
在线询价
优    惠: 请询价
订货号 0BC4915
品牌型号 Abinscience DK421028-96T
库存 有库存
最小订货量 1件
联系我们
  • 400-920-3909
AbinscienceELISA其它型号产品
  • 商品介绍
  • 规格参数
  • 包装参数
技术参数 Specifications
Stability and StorageThe stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Detection methodColorimetric
Sample typePlasma, Serum
Assay typeQuantitative
Sensitivity0.156 μg/ml
Range0.31-5 μg/mL
Recovery80-120%
BackgroundPalivizumab (brand name Synagis) is a humanized IgG monoclonal antibody (mAb) manufactured by MedImmune with recombinant DNA technology. It is used in the prevention of respiratory syncytial virus (RSV) infections. It is recommended for infants that are high-risk because of prematurity or other medical problems such as congenital heart disease. Palivizumab directed against an epitope in the A antigenic site of the F protein of RSV. Palivizumab is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor and Cess. The human light chain sequence was derived from the constant domain of Cκ and the variable framework regions of the VL gene K104 with Jκ -4. The murine sequences were derived from a murine monoclonal antibody, Mab 1129, in a process that involved the grafting of the murine complementarity determining regions into the human antibody frameworks. Palivizumab is composed of two heavy chains and two light chains and has a molecular weight of approximately 148,000 Daltons. Palivizumab was approved for medical use in 1998 but the indications for prophylaxis vary worldwide. Palivizumab is primarily indicated for the following conditions: prematurity (gestational age ≤ 35 weeks), bronchopulmonary dysplasia/chronic lung disease, hemodynamically significant congenital heart disease, and other serious medical disorders on an ad hoc basis. Infants with these medical conditions are at increased risk of more severe disease and more serious subsequent sequelae.
Alternative NamesMEDI-493, CAS: 188039-54-5,MEDI493, SYNAGIS, Humanized MAb 1129,1129
Shipping2-8 ℃
SpecificationsPalivizumab
NoteFor Research Use Only.
长度(mm)
宽度(mm)
高度(mm)
重量(kg)
猜你喜欢

在线
客服

在线客服服务时间:09:00-18:00

客服
热线

400-920-3909
客服服务热线 周一至周五(09:00-18:00)

微信
咨询

微信小程序 7X24小时在线咨询